Compositions and methods for inhibiting PDGFRbeta and VEGF-A
US9708390B2 · kind B2 · utility
6Cited by
8References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 11, 2016 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | Jul 11, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are antagonists of PDGF receptor β (PDGFRβ) and VEGF-A, including neutralizing anti-PDGFRβ and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRβ and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRβ and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRβ and/or VEGF-A antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.